A new tool to assess Clinical Diversity In Meta-analyses (CDIM) of interventions
(2021) In Journal of Clinical Epidemiology 135. p.29-41- Abstract
Objective: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical diversity between trials in meta-analyses of interventions. Study design and setting: The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups. Results: CDIM measures clinical diversity on a scale that includes four domains with 11 items overall: setting (time of conduct/country development status/units type); population (age, sex, patient inclusion criteria/baseline disease severity, comorbidities); interventions (intervention intensity/strength/duration of... (More)
Objective: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical diversity between trials in meta-analyses of interventions. Study design and setting: The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups. Results: CDIM measures clinical diversity on a scale that includes four domains with 11 items overall: setting (time of conduct/country development status/units type); population (age, sex, patient inclusion criteria/baseline disease severity, comorbidities); interventions (intervention intensity/strength/duration of intervention, timing, control intervention, cointerventions); and outcome (definition of outcome, timing of outcome assessment). The CDIM is completed in two steps: first two authors independently assess clinical diversity in the four domains. Second, after agreeing upon scores of individual items a consensus score is achieved. Interrater scale reliability and agreement ranged from moderate to almost perfect depending on the type of raters. Conclusion: CDIM is the first tool developed for assessing clinical diversity in meta-analyses of interventions. We found CDIM to be a reliable tool for assessing clinical diversity among trials in meta-analysis.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Diversity, Evidence, Heterogeneity, Meta-analysis, Quality, Systematic review, Tool
- in
- Journal of Clinical Epidemiology
- volume
- 135
- pages
- 13 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85102038804
- pmid:33561529
- ISSN
- 0895-4356
- DOI
- 10.1016/j.jclinepi.2021.01.023
- language
- English
- LU publication?
- yes
- id
- efb7aa82-453c-45b9-a75c-3305460c540c
- date added to LUP
- 2021-03-16 10:49:07
- date last changed
- 2024-09-19 18:07:36
@article{efb7aa82-453c-45b9-a75c-3305460c540c, abstract = {{<p>Objective: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical diversity between trials in meta-analyses of interventions. Study design and setting: The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups. Results: CDIM measures clinical diversity on a scale that includes four domains with 11 items overall: setting (time of conduct/country development status/units type); population (age, sex, patient inclusion criteria/baseline disease severity, comorbidities); interventions (intervention intensity/strength/duration of intervention, timing, control intervention, cointerventions); and outcome (definition of outcome, timing of outcome assessment). The CDIM is completed in two steps: first two authors independently assess clinical diversity in the four domains. Second, after agreeing upon scores of individual items a consensus score is achieved. Interrater scale reliability and agreement ranged from moderate to almost perfect depending on the type of raters. Conclusion: CDIM is the first tool developed for assessing clinical diversity in meta-analyses of interventions. We found CDIM to be a reliable tool for assessing clinical diversity among trials in meta-analysis.</p>}}, author = {{Barbateskovic, Marija and Koster, Thijs M. and Eck, Ruben J. and Maagaard, Mathias and Afshari, Arash and Blokzijl, Fredrike and Cronhjort, Maria and Dieperink, Willem and Fabritius, Maria L. and Feinberg, Josh and French, Craig and Gareb, Barzi and Geisler, Anja and Granholm, Anders and Hiemstra, Bart and Hu, Ruixue and Imberger, Georgina and Jensen, Bente T. and Jonsson, Andreas B. and Karam, Oliver and Kong, De Zhao and Korang, Steven K. and Koster, Geert and Lai, Baoyong and Liang, Ning and Lundstrøm, Lars H. and Marker, Søren and Meyhoff, Tine S. and Nielsen, Emil E. and Nørskov, Anders K. and Munch, Marie W. and Risom, Emilie C. and Rygård, Sofie L. and Safi, Sanam and Sethi, Naqash and Sjövall, Fredrik and Lauridsen, Susanne V. and van Bakelen, Nico and Volbeda, Meint and van der Horst, Iwan C.C. and Gluud, Christian and Perner, Anders and Møller, Morten H. and Keus, Eric and Wetterslev, Jørn}}, issn = {{0895-4356}}, keywords = {{Diversity; Evidence; Heterogeneity; Meta-analysis; Quality; Systematic review; Tool}}, language = {{eng}}, pages = {{29--41}}, publisher = {{Elsevier}}, series = {{Journal of Clinical Epidemiology}}, title = {{A new tool to assess Clinical Diversity In Meta-analyses (CDIM) of interventions}}, url = {{http://dx.doi.org/10.1016/j.jclinepi.2021.01.023}}, doi = {{10.1016/j.jclinepi.2021.01.023}}, volume = {{135}}, year = {{2021}}, }